Text size: AAA
Step into summer in the best shape of your life with these reports from Harvard Medical School.
Learn How

Start your exercise and fitness program and reap the benefits of being more fit, stronger and healthier!

Warmer weather is on the way and it's not too late to get in shape for the summer. These 3 reports can help you enjoy outdoor activities in the best shape of your life:

References for "Understanding the risks of antipsychotic treatment in young people"

MAR 2009

Next Article:

Did you know?

You can get instant online access to all of the articles from the March 2009 issue of Harvard Mental Health Letter for only $5.

Already a subscriber? Login for complete instant access.

If you want a button/link to remove the box (not sure if you do or not...), it would look like this: Cancel

Blackburn GL. Break Through Your Set Point (HarperCollins Publishers, 2007).

“Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,” Journal of Clinical Psychiatry (Feb. 2004): Vol. 65, No. 2, pp. 267–72. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15003083

Cooper WO, et al. “New Users of Antipsychotic Medications Among Children Enrolled in TennCare,” Archives of Pediatric and Adolescent Medicine (Aug. 2004): Vol. 158, No. 8, pp. 753–59. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15289247

Correll CU. “Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes,” Journal of the American Academy of Child and Adolescent Psychiatry (Jan. 2008): Vol. 47, No. 1, pp. 9–20. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18174821

Correll CU, et al. “Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents,” Child and Adolescent Psychiatry Clinics of North America (Jan. 2006): Vol. 15, No. 1, pp. 177–206. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16321730

Correll CU. “Weight Gain and Metabolic Effects of Mood Stabilizers and Antipsychotics in Pediatric Bipolar Disorder: A Systematic Review and Pooled Analysis of Short-Term Trials,” Journal of the American Academy of Child and Adolescent Psychiatry (June 2007): Vol. 46, No. 6, pp. 687–700. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17513981

Domino ME, et al. “Who Are the New Users of Antipsychotic Medications?” Psychiatric Services (May 2008): Vol. 59, No. 5, pp. 507–14. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18451006

Gutgesell H, et al. “AHA Scientific Statement: Cardiovascular Monitoring of Children and Adolescents Receiving Psychotropic Drugs,” Journal of the American Academy of Child and Adolescent Psychiatry (Aug. 1999): Vol. 38, No. 8, pp. 1047-50.

Jensen PS, et al. “Management of Psychiatric Disorders in Children and Adolescents with Atypical Antipsychotics: A Systematic Review of Published Clinical Trials,” European Child and Adolescent Psychiatry (March 2007): Vol. 16, No. 2, pp. 104–20. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17075688

Jerrell JM, et al. “Neurological Adverse Events Associated With Antipsychotic Treatment in Children and Adolescents,” Journal of Child Neurology (Dec. 2008): Vol. 23, No. 12, pp. 1392-99. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18772491

Kumanov P, et al. “Relationship of Adolescent Gynecomastia with Varicocele and Somatometric Parameters: A Cross-Sectional Study in 6,200 Healthy Boys,” Journal of Adolescent Health (Aug. 2007): Vol. 41, No. 2, pp. 126–31.

Martin A, et al. “Triglyceride, Cholesterol and Weight Changes Among Risperidone-Treated Youths. A Retrospective Study,” European Child and Adolescent Psychiatry (June 2002): Vol. 11, No. 3, pp. 129–33. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12369772

McIntyre RS, et al. “Metabolic and Cardiovascular Adverse Events Associated with Antipsychotic Treatment in Children and Adolescents,” Archives of Pediatric and Adolescent Medicine (Oct. 2008): Vol. 162, No. 10, pp. 929–35. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18838645

Olfson M, et al. “National Trends in the Outpatient Treatment of Children and Adolescents with Antipsychotic Drugs,” Archives of General Psychiatry (June 2006): Vol. 63, No. 6, pp. 679–85. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16754841

Shin L, et al. “An Overview of Obesity in Children with Psychiatric Disorders Taking Atypical Antipsychotics,” Harvard Review of Psychiatry (March–April 2008): Vol. 16, No. 2, pp. 69–79. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18415880

Sikich L, et al. “A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial,” Neuropsychopharmacology (Jan. 2004): Vol. 29, No. 1, pp. 133–45. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14583740

Sikich L, et al. “Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizoaffective Disorder: Findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study,” American Journal of Psychiatry (Nov. 2008): Vol. 165, No. 11, pp. 1420-31.

Zito JM, et al. “Psychotherapeutic Medication Prevalence in Medicaid-Insured Preschoolers,” Journal of Child and Adolescent Psychopharmacology (April 2007): Vol. 17, No. 2, pp. 195–203. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17489714

Next Article: